China Cash Conversion Cycle from 2010 to 2026
| SXTC Stock | USD 2.38 0.12 5.31% |
Cash Conversion Cycle | First Reported 2010-12-31 | Previous Quarter 279.56 | Current Value 220.01 | Quarterly Volatility 189.32883675 |
Check China SXT financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among China SXT's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Interest Income of 4.4 K or Depreciation And Amortization of 89.9 K, as well as many indicators such as Price To Sales Ratio of 105, Dividend Yield of 0.0 or PTB Ratio of 10.7. China financial statements analysis is a perfect complement when working with China SXT Valuation or Volatility modules.
China | Cash Conversion Cycle | Build AI portfolio with China Stock |
Analyzing China SXT's Cash Conversion Cycle over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Cash Conversion Cycle has evolved provides context for assessing China SXT's current valuation and future prospects.
Latest China SXT's Cash Conversion Cycle Growth Pattern
Below is the plot of the Cash Conversion Cycle of China SXT Pharmaceuticals over the last few years. It is China SXT's Cash Conversion Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in China SXT's overall financial position and show how it may be relating to other accounts over time.
| Cash Conversion Cycle | 10 Years Trend |
|
Cash Conversion Cycle |
| Timeline |
China Cash Conversion Cycle Regression Statistics
| Arithmetic Mean | 216.42 | |
| Geometric Mean | 158.58 | |
| Coefficient Of Variation | 87.48 | |
| Mean Deviation | 145.80 | |
| Median | 130.09 | |
| Standard Deviation | 189.33 | |
| Sample Variance | 35,845 | |
| Range | 600 | |
| R-Value | 0.43 | |
| Mean Square Error | 31,113 | |
| R-Squared | 0.19 | |
| Significance | 0.08 | |
| Slope | 16.18 | |
| Total Sum of Squares | 573,527 |
China Cash Conversion Cycle History
About China SXT Financial Statements
China SXT stakeholders use historical fundamental indicators, such as China SXT's Cash Conversion Cycle, to determine how well the company is positioned to perform in the future. Although China SXT investors may analyze each financial statement separately, they are all interrelated. For example, changes in China SXT's assets and liabilities are reflected in the revenues and expenses on China SXT's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in China SXT Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Cash Conversion Cycle | 279.56 | 220.01 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether China SXT Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China SXT's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Sxt Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on China Sxt Pharmaceuticals Stock:Check out the analysis of China SXT Correlation against competitors. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Will Personal Care Products sector continue expanding? Could China diversify its offerings? Factors like these will boost the valuation of China SXT. If investors know China will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every China SXT data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.426 | Earnings Share (57.15) | Revenue Per Share | Quarterly Revenue Growth (0.24) | Return On Assets |
The market value of China SXT Pharmaceuticals is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China SXT's value that differs from its market value or its book value, called intrinsic value, which is China SXT's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because China SXT's market value can be influenced by many factors that don't directly affect China SXT's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China SXT's value and its price as these two are different measures arrived at by different means. Investors typically determine if China SXT is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, China SXT's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.